BioAtla, Inc. (BCAB)
1.71
+0.48
(+39.02%)
USD |
OTCM |
Oct 23, 16:00
BioAtla Net Income (Quarterly) : 0.452M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.452M |
| March 31, 2026 | -6.344M |
| December 31, 2025 | -9.784M |
| September 30, 2025 | -15.78M |
| June 30, 2025 | -18.71M |
| March 31, 2025 | -15.33M |
| December 31, 2024 | -14.88M |
| September 30, 2024 | -10.59M |
| June 30, 2024 | -21.07M |
| March 31, 2024 | -23.23M |
| December 31, 2023 | -26.92M |
| September 30, 2023 | -33.32M |
| June 30, 2023 | -35.75M |
| March 31, 2023 | -27.46M |
| Date | Value |
|---|---|
| December 31, 2022 | -27.54M |
| September 30, 2022 | -25.78M |
| June 30, 2022 | -28.91M |
| March 31, 2022 | -24.25M |
| December 31, 2021 | -23.39M |
| September 30, 2021 | -22.93M |
| June 30, 2021 | -30.38M |
| March 31, 2021 | -18.70M |
| December 31, 2020 | -16.40M |
| September 30, 2020 | -11.63M |
| June 30, 2020 | -6.222M |
| March 31, 2020 | -1.604M |
| December 31, 2019 | -1.358M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 6.50M |
| Total Expenses (Quarterly) | 6.048M |
| EPS Diluted (Quarterly) | 0.272 |
| Enterprise Value | 7.163M |
| Profit Margin (Quarterly) | 6.95% |
| Earnings Yield | -1.49K% |
| Normalized Earnings Yield | -1507.75 |